Trials / Recruiting
RecruitingNCT07451002
A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France
An OBServational Prospective Study in France: Adherence to APAlutamide in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Patients in France
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 270 (estimated)
- Sponsor
- Janssen Cilag S.A.S. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to explore the real-world treatment adherence, persistence of apalutamide, and assess the risk of non-adherence according to the participant's profile and behavior of metastatic hormone-sensitive prostate cancer (mHSPC) participants treated with apalutamide during the first year of continued treatment.
Conditions
Timeline
- Start date
- 2025-12-18
- Primary completion
- 2028-01-03
- Completion
- 2028-01-03
- First posted
- 2026-03-05
- Last updated
- 2026-04-13
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT07451002. Inclusion in this directory is not an endorsement.